CYH at a glance
COMMUNITY HEALTH SYSTEMS INC (CYH, SEC CIK 1108109) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as August 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), COMMUNITY HEALTH SYSTEMS INC (CYH) reported revenue of $12.5 billion (down 1.2% from FY2024) and net income of $509.0 million. Diluted EPS was $3.77.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding COMMUNITY HEALTH SYSTEMS INC (CYH) shares worth $122.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by JENNINGS WILLIAM NORRIS on August 25, 2026 of 40,000 shares at $2.96 per share.
- In the last 90 days, CYH insiders reported 0 open-market purchases ($0) and 1 open-market sale ($118K) on Form 4, a net sale of $118K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $12.5B
- −1.2% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$118K
- 13F holders
- 27 funds
- $122.3M · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors in the 2025 Form 10-K
Management Discussion & Analysis
- Quarterly revenue $2.757B, down 10.7% YoY from $3.087B; same-store revenue up $100M, or 3.8%
- Operating margin 5.3% vs 7.9% YoY; net margin (1.8)% vs 5.5%, with net loss $(50)M vs $171M income
- Same-store adjusted admissions up 3.6%, while consolidated adjusted admissions fell 11.9%; no product-line profitability disclosed
- Operating cash flow $(55)M vs $277M provided; investing cash flow $894M, including increased hospital disposition proceeds
- $600M deployed for debt repurchases; 2026 capital expenditure outlook $350M to $400M amid Medicaid cuts and uninsured-patient headwinds
AI summary of the CYH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Proposed exchange targets all outstanding 6.875% Junior-Priority Secured Notes due 2029
- New debt would carry a higher 10.250% coupon, increasing interest burden
Item EX-99.1: Item EX-99.1
- Proposed exchange of $1,244.476M 6.875% 2029 notes into 10.250% senior secured notes due 2035
- Higher coupon increases annual interest burden, while extending maturity by six years
Item EX-99.1: Item EX-99.1
- Q3 revenue $2.757B, down 10.7%, while same-store revenue rose 3.8%, indicating divestitures materially reduced reported scale
- Net loss $(86)M, or $(0.63) per diluted share, versus $130M profit and $0.96 EPS in Q3 2025
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 operating results announced for quarter ended September 30, 2026
- Press release attached as Exhibit 99.1, containing the disclosed financial results and management commentary
Item 7.01: Regulation FD Disclosure
- 2026 updated annual earnings guidance announced through the Item 2.02 press release
- Guidance assumptions span historical performance, current trends and management expectations
Item EX-99.1: Item EX-99.1
- Q2 revenue $2.825B, down 9.8%; same-store revenue increased 2.4%, indicating divestitures drove reported contraction
- Adjusted EBITDA $330M, down 13.2%, with margin declining to 11.7% from 12.1%
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 operating results announced for quarter ended June 30, 2026
- Press release dated July 22, 2026 contains the substantive financial results in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Updated 2026 annual earnings guidance announced alongside the company’s earnings release
- Guidance reflects historical operating performance, current trends and management assumptions
AI summaries of CYH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CYH
Don't miss the next CYH filing
- Alerts as it files. A push when CYH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CYH, by share count.
- Ask anything. An AI agent that reads every CYH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| JENNINGS WILLIAM NORRIS | Sell | Aug 25, 2026 | 40,000 | $2.96 |
| Krishnan K Ranga | M | Jun 30, 2026 | 13,930 | - |
| Krishnan K Ranga | M | Jun 30, 2026 | 13,930.678 | - |
| Rice David V. | A | Jun 1, 2026 | 30,000 | - |
| Rice David V. | A | Jun 1, 2026 | 30,000 | - |
| Rice David V. | A | Jun 1, 2026 | 30,000 | - |
| Krishnan K Ranga | M | Apr 22, 2026 | 46,950 | - |
| Krishnan K Ranga | M | Apr 22, 2026 | 46,950 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $12.6B | $12.5B |
| Operating Income | - | $542.0M | $1.5B |
| Net Income | -$133.0M | -$516.0M | $509.0M |
| Op. Margin | - | 4.3% | 11.9% |
| Net Margin | - | -4.1% | 4.1% |
| Balance Sheet | |||
| Total Assets | $14.5B | $14.1B | $13.2B |
| Equity | - | -$1.9B | -$1.4B |
| ROE | - | 27.0% | -36.5% |
| Per Share | |||
| EPS | $-1.02 | $-3.90 | $3.77 |
| Cash Flow | |||
| Operating CF | - | $480.0M | $543.0M |
| CapEx | $467.0M | $360.0M | $335.0M |
Source: XBRL data in COMMUNITY HEALTH SYSTEMS INC (CYH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CYH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $122.3M |
| Q2 2026 | 27 | $136.7M |
| Q1 2026 | 27 | $113.4M |
| Q4 2025 | 25 | $122.5M |
| Q3 2025 | 28 | $126.9M |
| Q2 2025 | 28 | $156.4M |
| Q1 2025 | 26 | $99.8M |
| Q4 2024 | 21 | $97.2M |
- JPMorgan Chase & Co+2.57M (+4704%)
- Goldman Sachs Group+1.18M (+67%)
- Citadel Advisors LLC+229.8K (+22%)
- Morgan Stanley+176.7K (+12%)
- State Street Corp+97.6K (+3%)
- AQR Capital Management−866.9K (-38%)
- Two Sigma Investments−623.5K (-28%)
- BlackRock−395.4K (-4%)
- Millennium Management−282.1K (-55%)
- Northern Trust−166.7K (-12%)
- Principal Financial Group+224.9K
- FMR LLC (Fidelity)−7.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 209 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CYH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 4 | Aug 25, 2026 | - | - | - |
| 10-Q | Jul 23, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | Jun 1, 2026 | - | - | |
| SC 13G | May 14, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 10-Q | Apr 22, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 22, 2026 | - | - | - |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
Related Health Care companies
- ARDT · Ardent Health, Inc.Services-General Medical & Surgical Hospitals, NEC
- HCA · HCA HealthcareServices-General Medical & Surgical Hospitals, NEC
- SGRY · Surgery Partners, Inc.Services-General Medical & Surgical Hospitals, NEC
- UHS · Universal Health ServicesServices-General Medical & Surgical Hospitals, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
CYH SEC filings: frequently asked questions
Are CYH insiders buying or selling?
In the last 90 days, COMMUNITY HEALTH SYSTEMS INC (CYH) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $118,400 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CYH stock?
As of September 30, 2026, the largest COMMUNITY HEALTH SYSTEMS INC (CYH) holders among the 13F filers tracked by SignalX were BlackRock ($30.1 million), Vanguard Capital Management LLC ($14.7 million), State Street Corp ($9.0 million), Vanguard Portfolio Management LLC ($8.5 million), Goldman Sachs Group ($8.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CYH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), COMMUNITY HEALTH SYSTEMS INC (CYH) reported revenue of $12.5 billion (down 1.2% from FY2024) and net income of $509.0 million. Diluted EPS was $3.77. The figures come from the XBRL data in the 10-K.
What did CYH report in its latest 8-K?
COMMUNITY HEALTH SYSTEMS INC (CYH) filed an 8-K on November 10, 2026 reporting Item 8.01 (Other Events). Proposed exchange targets all outstanding 6.875% Junior-Priority Secured Notes due 2029.
What are the latest CYH SEC filings?
COMMUNITY HEALTH SYSTEMS INC (CYH) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on August 25, 2026.
What is CYH's SEC CIK number?
COMMUNITY HEALTH SYSTEMS INC (CYH)'s SEC Central Index Key (CIK) is 1108109. EDGAR lists every CYH filing under that number.
Ask anything about CYH
The research agent reads CYH's filings, financials, insider trades and 13F holders, then answers with sources.